Marcoumar

Phenprocoumon, the active ingredient in Marcoumar, is a Coumarin anticoagulant presented as an oral tablet for oral use. It is employed to prevent and treat thromboembolic disorders such as deep‑vein thrombosis, pulmonary embolism, and stroke in patients with atrial fibrillation or prosthetic heart valves.

GNH USA supplies Marcoumar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance through rigorous testing and validated manufacturing processes.

Phenprocoumon is used to manage conditions that involve abnormal blood clot formation.

- Deep‑vein thrombosis: prevents clot extension and recurrence in patients with DVT. - Pulmonary embolism: treats and reduces the risk of recurrent embolic events. - Atrial fibrillation (stroke prevention): lowers the incidence of ischemic stroke in non‑valvular AF. - Prosthetic heart valves: provides long‑term anticoagulation to avoid valve‑related thrombosis.

Phenprocoumon may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bruising or easy bruising. - Bleeding gums or nosebleeds. - Gastrointestinal discomfort or dyspepsia. - Headache or dizziness. - Skin rash or mild itching. - Minor hematuria.

Serious or Rare Side Effects: - Severe internal bleeding (e.g., intracranial or gastrointestinal). - Skin necrosis or severe cutaneous reactions. - Hepatic enzyme elevation or liver dysfunction. - Allergic anaphylaxis. - Thrombocytopenia. - Adrenal insufficiency or other endocrine disturbances.

Patients receiving Phenprocoumon should be monitored closely for safety and efficacy.

- INR monitoring: maintain therapeutic range as directed by a healthcare professional. - Liver disease: adjust dose or avoid use in significant hepatic impairment. - Surgery or invasive procedures: discontinue or bridge therapy according to clinical guidance. - Elderly patients: start with lower doses and monitor for bleeding. - Pregnancy: contraindicated; avoid use in pregnant women (Category X). - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Phenprocoumon interacts with several medicines that can alter its anticoagulant effect.

Major Interactions (Avoid): - Other anticoagulants (e.g., heparin, direct oral anticoagulants): markedly increased bleeding risk. - Strong CYP2C9 inhibitors (e.g., amiodarone, fluconazole, metronidazole): may cause excessive anticoagulation. - Antiplatelet agents (e.g., aspirin, clopidogrel): additive bleeding potential.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., macrolides, quinolones): may modestly increase INR. - SSRIs or SNRIs: can enhance bleeding tendency. - Vitamin K–containing supplements or foods: may reduce anticoagulant effect. - Thyroid hormones: may alter drug metabolism and INR stability.